Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus SITAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus SITAGLIPTIN.
JANUVIA vs SITAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
100 mg orally once daily
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Clinical Note
moderateSitagliptin + Gatifloxacin
"Sitagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSitagliptin + Rosoxacin
"Sitagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSitagliptin + Levofloxacin
"Sitagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSitagliptin + Trovafloxacin
"Sitagliptin may increase the hypoglycemic activities of Trovafloxacin."
12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition.
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor